SCHEMBL30135201

SCHEMBL30135201

CCc1cc(NC(=O)[C@H](NC(=O)OC(C)(C)C)C(C)(C)C)ccc1Br

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSS P25774 3/20 0.42
CTSK P43235 3/20 0.42
CA2 P00918 2/20 0.40
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA4 P22748 1/20 0.40
CA9 Q16790 1/20 0.40
EGFR P00533 3/20 0.40
HDAC4 P56524 2/20 0.39
HDAC1 Q13547 2/20 0.39
AAK1 Q2M2I8 3/20 0.39
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
HDAC8 Q9BY41 2/20 0.38
HDAC3 O15379 1/20 0.38
HDAC7 Q8WUI4 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC10 Q969S8 1/20 0.38
HDAC11 Q96DB2 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30135221 0.81 MEN1 (0.50) CTSSCTSKAAK1KMT2AMEN1
SCHEMBL13664872 0.78 SMN1; SMN2 (0.45) CA2CA4CA9EGFRKMT2A
SCHEMBL30134918 0.78 ALDH1A1 (0.45) CA2CA12CA1CA4CA9
SCHEMBL16744644 0.75 SREBF2 (0.46) CA12CA1CA9HDAC1KMT2A
SCHEMBL38657707 0.75 CA12 (0.45) CA12CA1CA9HDAC1KMT2A
SCHEMBL7403819 0.74 MMP2 (0.50) AAK1TSHRMAPK1
SCHEMBL28438966 0.74 PDK1 (0.58) CA2CA1CA9KMT2AMEN1
SCHEMBL28302624 0.74 PDK1 (0.58) CA2CA1CA9KMT2AMEN1
SCHEMBL10323721 0.73 CA12 (0.43) CA12CA1CA9HDAC1KMT2A
SCHEMBL849264 0.72 CA12 (0.48) CTSSCTSKCA2CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250243196-A1 CITRON KINASE INHIBITORS THE CLEVELAND CLINIC FOUNDATION 2025-07-31 US disclosed
WO-2022216717-A1 CITRON KINASE INHIBITORS THE CLEVELAND CLINIC FOUNDATION (US) 2022-10-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250243196-A1 CITRON KINASE INHIBITORS CHEK2, CILK1, DCK CTSS 3694/4885CTSK 851/4885CA2 1566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.